MedTrace Logo

ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)

NCT06730412 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 103

Last updated 2025-12-04

No results posted yet for this study

Summary

The purpose of this study is to test a new liquid biopsy assay for detecting residual disease after surgery in patients with HPV-associated head and neck cancer.

Conditions

  • HPV Positive Oropharyngeal Squamous Cell Carcinoma

Sponsors & Collaborators

  • National Institute of Dental and Craniofacial Research (NIDCR)

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • Massachusetts General Hospital

    collaborator OTHER

  • Massachusetts Eye and Ear Infirmary

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2024-10-31
Completion
2024-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06730412 on ClinicalTrials.gov